Doylestown, Pennsylvania-based Aprea Therapeutics, Inc. is making strides in its mission to create and distribute cancer therapeutics that utilize synthetic lethality. The biopharmaceutical company is concentrating its efforts on attacking a critical DNA damage response pathway and central targets in cancer progression. ATRN-119, the firm's premier program, is a small molecule ATR inhibitor that is currently undergoing clinical testing for the treatment of solid tumors.
Aprea Therapeutics, Inc.'s ticker is APRE
The company's shares trade on the NASDAQ stock exchange
They are based in Boston, Massachusetts
There are 11-50 employees working at Aprea Therapeutics, Inc.
It is https://www.aprea.com/
Aprea Therapeutics, Inc. is in the Healthcare sector
Aprea Therapeutics, Inc. is in the Biotechnology industry
The following five companies are Aprea Therapeutics, Inc.'s industry peers: